Search

everythinglearnresearchcommunity

for

Search:↓

Patients should discuss complementary medicine use with doctors to improve health outcomes.

Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.

No increased skin cancer risk was found in alopecia patients treated with photobiomodulation.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.

A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

Genetic testing for cancer risk can lead to early and life-saving treatments in people without symptoms.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

Chemotherapy causes hair loss in cancer patients by affecting both growing and resting hair.

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.

Medical castration in prostate cancer patients can increase the risk of serious heart rhythm problems, so it's important to monitor heart activity during treatment.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Oncologists should better understand the unique impact of hair loss on Black breast cancer patients to offer more compassionate care.

PPX causes much less hair loss than traditional taxanes.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.

Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.

Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.

Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.